| 1. |
Jaffe E, Harris N, Stein H, et al. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues[M]. Lyon:IARC Press, 2001:171-175.
|
| 2. |
王志伟, 邓国华. EB病毒感染与淋巴瘤[J]. 内科理论与实践, 2007, 2(4):275-276.
|
| 3. |
Thompson MP, Kurzrock R. Epstein-Barr virus and cancer[J]. Clin Cancer Res, 2004, 10(3):803-821.
|
| 4. |
Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma[J]. Lancet, 1964, 283(7335):702-703.
|
| 5. |
Swerdllow SH, Campo E, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues[M]. Lyon:IARC Press, 2008.
|
| 6. |
Oyama T, Ichimura K, Suzuki R, et al. Senile EBV+B-cell lymphoproliferative disorders:a clinicopathologic study of 22 patients[J]. Am J Surg Pathol, 2003, 27(1):16-26.
|
| 7. |
Ok CY, Papathomas TG, Medeiros L. EBV-positive diffuse large B-cell lymphoma of the elderly[J]. Blood, 2013, 122(3):328-340.
|
| 8. |
Hoeller S, Tzankov A, Pileri SA, et al. Epstein-Barr virus positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations[J]. Hum Pathol, 2010, 41(3):352-357.
|
| 9. |
Castillo JJ, Beltran BE, Miranda RN, et al. Epstein-Barr virus-positive diffuse large B-Cell lymphoma of the elderly:what we know so far[J]. Oncologist, 2011, 16(1):87-96.
|
| 10. |
Montes-Moreno S, Odqvist L, Diaz-Perez JA, et al. EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation[J]. Mod Pathol, 2012, 25(7):968-982.
|
| 11. |
Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma[J]. Blood, 2007, 110(3):972-978.
|
| 12. |
Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-Cell lymphoma and mantle cell lymphoma[J]. J Clin Oncol, 2011, 29(6):690-697.
|
| 13. |
Barreto L, Azambuja D, De Morais JC. Expression of immunohistochemical markers in patients with AIDS-related lymphoma[J]. Braz J Infect Dis, 2012, 16(1):74-77.
|
| 14. |
Chao C, Silverberg MJ, Martinez-Maza OA, et al. Epstein-Barr virus infection and expression of B-cell oncogenic markers in HIV-related diffuse large B-cell lymphoma[J]. Clin Cancer Res, 2012, 18(17):4702-4712.
|
| 15. |
Tumwine LK, Orem J, Kerchan P, et al. Research article EBV, HHV8 and HIV in B cell non Hodgkin lymphoma in Kampala, Uganda[J]. Infect Agent Cancer, 2010, 5:12.
|
| 16. |
Matthews GV, Bower M, Mandalia S, et al. Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy[J]. Blood, 2000, 96(8):2730-2734.
|
| 17. |
Dunleavy K, Wilson WH. How I treat HIV-associated lymphoma[J]. Blood, 2012, 119(14):3245-3255.
|
| 18. |
Kaplan LD. HIV-associated lymphoma[J]. Best Pract Res Clin Haematol, 2012, 25(1):101-117.
|
| 19. |
Dalia S, Chavez J, Castillo JJ, et al. Hepatitis B infection increases the risk of non-Hodgkin lymphoma:a meta-analysis of observational studies[J]. Leuk Res, 2013, 37(9):1107-1115.
|
| 20. |
Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea:a cohort study[J]. Lancet Oncol, 2010, 11(9):827-834.
|
| 21. |
Nieters A, Kallinowski B, Brennan P, et al. Hepatitis C and risk of lymphoma:results of the European Multicenter Case-Control Study EPILYMPH[J]. Gastroenterology, 2006, 131(6):1879-1886.
|
| 22. |
Visco C, Arcaini L, Brusamolino E, et al. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma:analysis of 156 patients from northern Italy[J]. Ann Oncol, 2006, 17(9):1434-1440.
|
| 23. |
Xie WZ, Zhou D, Hu KY, et al. Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy[J]. Exp Ther Med, 2013, 6(1):109-114.
|
| 24. |
Chen XQ, Peng JW, Lin GN, et al. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy[J]. Med Oncol, 2012, 29(2):1237-1241.
|
| 25. |
Ennishi D, Maeda Y, Niitsu N, et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens:a Japanese multicenter analysis[J]. Blood, 2010, 116(24):5119-5125.
|
| 26. |
Nishikawa H, Tsudo M, Osaki Y. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era:a single center experience[J]. Oncol Rep, 2012, 28(3):835-840.
|
| 27. |
Nooka A, Shenoy PJ, Sinha R, et al. Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab:a case report and review of literature[J]. Clin Lymphoma Myeloma Leuk, 2011, 11(5):379-384.
|
| 28. |
Beltran BE, Quinones P, Morales D, et al. Diffuse large B-cell lymphoma in human T-lymphotropic virus type 1 carriers[J]. Leuk Res Treatment, 2012, 2012:1-4.
|
